Why Many Physicians Are Reluctant to Recommend HBOT

Hyperbaric oxygen therapy occupies an unusual position in medicine. For its approved indications, including diabetic foot ulcers, radiation injury, carbon monoxide poisoning, and decompression sickness, it is an established intervention with decades of clinical use and a clear evidence base. Yet many physicians, including specialists who regularly treat conditions for which HBOT has meaningful supporting research, remain reluctant to recommend it.

That reluctance is not simply a matter of ignorance. It reflects a set of real structural, institutional, and evidentiary factors that shape how physicians engage with any intervention that sits outside the mainstream of their training and practice environment. Understanding those factors is useful for patients who have been told that HBOT is not relevant to their situation, and for anyone trying to navigate the gap between what the research suggests and what is routinely offered in clinical settings.

The Training Gap

The most fundamental reason many physicians are unfamiliar with HBOT is that it receives minimal coverage in standard medical education. Hyperbaric medicine is a subspecialty, and formal training in it is pursued by a relatively small number of physicians, typically those working in wound care centres, diving medicine, or dedicated hyperbaric units.

For the majority of physicians, including general practitioners, neurologists, oncologists, and rehabilitation specialists, HBOT is simply not part of their clinical training. They may have encountered it briefly in a lecture on decompression sickness or carbon monoxide poisoning, but they will not have developed a working understanding of its mechanisms, its approved indications, or the emerging research in areas like traumatic brain injury, post viral syndromes, or neurological recovery.

This is not a criticism. Medical training involves difficult choices about what to include and what to leave out, and the breadth of knowledge required across all specialties is enormous. But it does mean that many physicians who encounter patients asking about HBOT are working from a limited foundation, and that limitation can manifest as scepticism or dismissal rather than informed engagement.

The Evidence Threshold Problem

Medicine operates on a hierarchy of evidence, with randomised controlled trials and systematic reviews at the top, and case reports and expert opinion at the bottom. That hierarchy exists for good reasons. It protects patients from interventions that are ineffective or harmful, and it provides a consistent framework for evaluating competing claims.

The challenge for HBOT is that its evidence base is uneven. For its approved indications, the evidence is strong and the clinical case is clear. For conditions like traumatic brain injury, long COVID, PTSD, and cognitive decline, the evidence is more recent, more variable in quality, and still accumulating. Some of the most compelling research, including the work of Professor Shai Efrati's group at the Sagol Center in Israel, has produced results that are difficult to dismiss, but the trials are often small, the protocols vary between studies, and replication by independent groups is still limited.

For a physician trained to apply a high evidentiary threshold before recommending any intervention, that picture is genuinely uncertain. The appropriate response to uncertainty is not necessarily refusal, but it is also not straightforward endorsement. Many physicians land on caution, which in practice means not recommending HBOT even when a patient might benefit from a more nuanced conversation about the evidence.

Institutional and Reimbursement Constraints

In many healthcare systems, the practical availability of HBOT is tightly constrained by reimbursement structures. In the United States, for example, Medicare and most private insurers cover HBOT only for the 14 indications approved by the Undersea and Hyperbaric Medical Society. For any condition outside that list, the cost falls entirely to the patient.

This creates a structural disincentive for physicians to recommend HBOT in off label contexts. If a physician recommends an intervention that is not covered by insurance, they are asking their patient to bear a significant financial burden. That is a difficult conversation, and many physicians avoid it by not raising the option at all.

There is also a liability dimension. Recommending an intervention that is not within standard of care for a given condition, even if the evidence is supportive, carries a degree of professional risk. In a medical legal environment where physicians are acutely aware of the consequences of departing from established protocols, that risk is not trivial.

The Wellness Industry Contamination Effect

HBOT has attracted significant interest from the wellness and biohacking communities, and that interest has had a complicated effect on how the therapy is perceived by mainstream medicine.

Soft shell portable chambers, which operate at pressures too low to produce the physiological effects associated with clinical HBOT, are marketed aggressively to consumers. Celebrity endorsements, unsubstantiated claims about anti ageing and performance enhancement, and a general conflation of wellness HBOT with clinical HBOT have created a perception problem for the field.

When a physician encounters a patient asking about HBOT, their reference point may be shaped by the most visible version of the therapy, which is often the wellness version rather than the clinical one. That association, with unregulated facilities, inflated claims, and a consumer market that operates largely outside medical oversight, makes it harder for physicians to engage seriously with the clinical evidence.

The distinction between a 1.3 ATA soft shell chamber and a 2.0 to 2.4 ATA hard shell clinical chamber is fundamental to understanding what HBOT can and cannot do. But that distinction is not widely understood outside the hyperbaric medicine community, and the noise generated by the wellness market makes it harder to have a clear eyed conversation about the clinical evidence.

Specialist Territorial Dynamics

In some clinical contexts, physician reluctance to recommend HBOT reflects less about the evidence and more about specialist territory. Neurologists, for example, have established treatment pathways for conditions like stroke, TBI, and cognitive decline. Those pathways involve medications, rehabilitation protocols, and interventions that sit within the neurologist's scope of practice and expertise.

HBOT sits outside that scope. It requires referral to a hyperbaric facility, which may not have an established relationship with the referring physician. It involves a treatment modality that the neurologist cannot directly supervise or adjust. And it raises questions about mechanism and efficacy that the neurologist may not feel equipped to evaluate.

The result is that HBOT can fall into a gap between specialties, not clearly owned by any single discipline, and therefore not clearly anyone's responsibility to recommend. Patients who might benefit from a referral conversation simply do not have it, not because their physician has considered and rejected HBOT, but because it has not entered the clinical conversation at all.

What This Means in Practice

For patients navigating this landscape, the practical implication is that physician reluctance is not always a reliable signal about whether HBOT is or is not appropriate for their situation. A physician who has not been trained in hyperbaric medicine, who is working within a reimbursement system that does not cover off label use, and who associates HBOT with the wellness market rather than the clinical evidence base, may decline to recommend it for reasons that have little to do with the evidence itself.

That does not mean patients should pursue HBOT against medical advice or outside a clinical framework. Clinical oversight matters, and the decision to pursue any intervention should involve a physician who understands the patient's full medical picture.

What it does mean is that a second opinion, or a conversation with a physician who has specific expertise in hyperbaric medicine, can be genuinely valuable. The gap between what the evidence supports and what is routinely offered in clinical settings is real, and navigating it requires access to informed guidance rather than simply deferring to the first clinical response.